Sequential Treatment with Eldecalcitol After PTH Improves Bone Mechanical Properties of Lumbar Spine and Femur in Aged Ovariectomized Rats
Tóm tắt
Parathyroid hormone (PTH) analogs have a powerful anabolic effect on bone and are used in the treatment of patients with severe osteoporosis. However, there are limitations to how long they can be safely administered. Withdrawal of PTH results in the cancelation of its effects, necessitating subsequent treatment to maintain the bone quantity and quality. This study assessed the effects of Eldecalcitol (ELD), an active vitamin D3 derivative, after PTH in estrogen-deficient osteoporotic rats. Six-month-old female rats were ovariectomized, and PTH administration was started 7 weeks later. After 4 weeks of PTH treatment, the animals were divided into three groups and either continued to receive PTH (PTH–PTH), or were switched to ELD (PTH–ELD) or vehicle (PTH–Veh) for an additional 4 weeks. In the femur, increased BMD by 4 weeks treatment of PTH was significantly reduced in PTH–Veh but not in PTH–PTH and PTH–ELD. The same tendency was observed in the lumbar vertebrae. MicroCT imaging and histomorphometry analysis revealed that the favorable bone structure changes by PTH administration were also maintained in the femurs and tibias of the PTH–PTH and PTH–ELD groups. Increased bone strength by 4-week treatment of PTH in lumber also maintained in PTH–ELD. Furthermore, minimodeling was observed in the PTH–ELD group. These results demonstrate that treatment with ELD sequentially following PTH prevented the bone quantity and strength reduction that accompanies PTH withdrawal in estrogen-deficient rats.
Tài liệu tham khảo
Andreopoulou P, Bockman RS (2015) Management of postmenopausal osteoporosis. Annu Rev Med 66:329–342
Jilka RL (2007) Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40:1434–1446
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510–516
Tashjian AH Jr, Goltzman D (2008) On the interpretation of rat carcinogenicity studies for human PTH(1–34) and human PTH(1–84). J Bone Miner Res 23:803–811
Finkelstein JS, Wyland JJ, Leder BZ, Burnett-Bowie SM, Lee H, Jüppner H, Neer RM (2009) Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 94:2495–2501
Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ, PaTH Study Investigators (2005) One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565
Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]. Osteoporos Int 15:992–997
Adami S, San Martin J, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A (2008) Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:87–94
Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134
Amugongo SK, Yao W, Jia J, Dai W, Lay YA, Jiang L, Harvey D, Zimmermann EA, Schaible E, Dave N, Ritchie RO, Kimmel DB, Lane NE (2014) Effect of sequential treatments with alendronate, parathyroid hormone (1–34) and raloxifene on cortical bone mass and strength in ovariectomized rats. Bone 67:257–268
Takano Y, Tanizawa T, Mashiba T, Endo N, Nishida S, Takahashi HE (1996) Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1–34) administration in ovariectomized rats. J Bone Miner Res 11:169–177
Takeda S, Sakai S, Tanaka K, Tomizawa H, Serizawa K, Yogo K, Urayama K, Hashimoto J, Endo K, Matsumoto Y (2017) Intermittent ibandronate maintains bone mass, bone structure, and biomechanical strength of trabecular and cortical bone after discontinuation of parathyroid hormone treatment in ovariectomized rats. Calcif Tissue Int 101:65–74
Yamamoto T, Hasegawa T, Sasaki M, Hongo H, Tsuboi K, Shimizu T, Ota M, Haraguchi M, Takahata M, Oda K, Luiz de Freitas PH, Takakura A, Takao-Kawabata R, Isogai Y, Amizuka N (2016) Frequency of teriparatide administration affects the histological pattern of bone formation in young adult male mice. Endocrinology 157:2604–2620
Ono Y (2014) Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol’s benefit in osteoporosis treatment. J Steroid Biochem Mol Biol 139:88–97
de Freitas PH, Hasegawa T, Takeda S, Sasaki M, Tabata C, Oda K, Li M, Saito H, Amizuka N (2011) Eldecalcitol, a second-generation vitamin D analog, drives bone minimodeling and reduces osteoclastic number in trabecular bone of ovariectomized rats. Bone 49:335–342
Saito H, Takeda S, Amizuka N (2013) Eldecalcitol and calcitriol stimulates ‘bone minimodeling,’ focal bone formation without prior bone resorption, in rat trabecular bone. J Steroid Biochem Mol Biol 136:178–182
Saito M, Grynpas MD, Burr DB, Allen MR, Smith SY, Doyle N, Amizuka N, Hasegawa T, Kida Y, Marumo K, Saito H (2015) Treatment with eldecalcitol positively affects mineralization, microdamage, and collagen crosslinks in primate bone. Bone 73:8–15
Takeda S, Saito M, Sakai S, Yogo K, Marumo K, Endo K (2017) Eldecalcitol, an active vitamin D3 derivative, prevents trabecular bone loss and bone fragility in type I diabetic model rats. Calcif Tissue Int 101:433–444
Sakai S, Endo K, Takeda S, Mihara M, Shiraishi A (2012) Combination therapy with eldecalcitol and alendronate has therapeutic advantages over monotherapy by improving bone strength. Bone 50:1054–1063
Villanueva AR (1974) A bone stain for osteoid seams in fresh, unembedded, mineralized bone. Stain Technol 49:1–8
Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595–610
Amizuka N, Kwan MY, Goltzman D, Ozawa H, White JH (1999) Vitamin D3 differentially regulates parathyroid hormone/parathyroid hormone-related peptide receptor expression in bone and cartilage. J Clin Invest 103:373–381
Oda K, Amaya Y, Fukushi-Irie M, Kinameri Y, Ohsuye K, Kubota I, Fujimura S, Kobayashi J (1999) A general method for rapid purification of soluble versions of glycosylphosphatidylinositol-anchored proteins expressed in insect cells: an application for human tissue-nonspecific alkaline phosphatase. J Biochem 126:694–699
Amizuka N, Takahashi N, Udagawa N, Suda T, Ozawa H (1997) An ultrastructural study of cell–cell contact between mouse spleen cells and calvaria-derived osteoblastic cells in a co-culture system for osteoclast formation. Acta Histochem Cytochem 30:351–362
Pettway GJ, Schneider A, Koh AJ, Widjaja E, Morris MD, Meganck JA, Goldstein SA, McCauley LK (2005) Anabolic actions of PTH (1–34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone 36:959–970
Samadfam R, Xia Q, Goltzman D (2007) Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice. J Bone Miner Res 22:55–63
Iwaniec UT, Samnegård E, Cullen DM, Kimmel DB (2001) Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1–84)]-treated rats by estrogen, risedronate, or reduced hPTH. Bone 29:352–360
Hasegawa T, Yamamoto T, Sakai S, Miyamoto Y, Hongo H, Qiu Z, Abe M, Takeda S, Oda K, de Freitas PHL, Li M, Endo K, Amizuka N (2018) Histological effects of the combined administration of eldecalcitol and a parathyroid hormone in the metaphyseal trabeculae of ovariectomized rats. J Histochem Cytochem. https://doi.org/10.1369/0022155418806865
O’Brien CA, Nakashima T, Takayanagi H (2013) Osteocyte control of osteoclastogenesis. Bone 54:258–263
Uchiyama Y, Higuchi Y, Takeda S, Masaki T, Shira-Ishi A, Sato K, Kubodera N, Ikeda K, Ogata E (2002) ED-71, a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone 30:582–588
Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures—a randomized, active comparator, double-blind study. Bone 49:605–612
Ji S, Doumit ME, Hill RA (2015) Regulation of adipogenesis and key adipogenic geneexpression by 1, 25-dihydroxyvitamin D in 3T3-L1 cells. PLoS ONE 10:e0126142
Narvaez CJ, Simmons KM, Brunton J, Salinero A, Chittur SV, Welsh JE (2013) Induction of STEAP4 correlates with 1,25-dihydroxyvitamin D3 stimulation of adipogenesis in mesenchymal progenitor cells derived from human adipose tissue. J Cell Physiol 228:2024–2036
Frost HM (1990) Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff’s law: the bone modeling problem. Anat Rec 226:403–413
Hikata T, Hasegawa T, Horiuchi K, Fujita N, Iwanami A, Watanabe K, Ishii K, Nakamura M, Amizuka N, Matsumoto M (2016) Histomorphometric analysis of minimodeling in the vertebrae in postmenopausal patients treated with anti-osteoporotic agents. Bone Rep 5:286–291